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cme.ctsnetjournals.org012 The Journal of Thoracic and Cardbjectives: The appropriate index of prosthesis internal orifice size and its effect on
perative mortality after aortic valve replacement are controversial. We examined
he association between several relevant indices and patient size on operative
ortality. Indices examined included projected in vivo effective orifice area and
eometric orifice area, with patient size defined as body surface area.
ethods: A review of the Society of Thoracic Surgeons National Cardiac Database
2000-2004) yielded 48,722 patients who had isolated aortic valve replacement.
his analysis is based on the cohort of 42,310 patients with the 8 most prevalent
alve types with manufacturer’s labeled sizes 19 mm through 29 mm. Multivariable
ogistic regression models were employed to determine the effects of body surface
rea, effective orifice area, geometric orifice area, and selected derived indices (eg,
ffective orifice area/body surface area) on risk-adjusted operative mortality.
esults: In separate multivariable models, effective orifice area and geometric orifice
rea were both inversely correlated with operative mortality. However, an unanticipated
nding was that with either effective orifice area or geometric orifice area held constant,
ody surface area was significantly and inversely correlated with operative mortality.
hen patients were stratified by effective orifice area, geometric orifice area, or
anufacturer’s labeled valve size and type, elevations in body surface area were
ssociated with a decrease rather than an increase in operative mortality.
onclusions: Prostheses with small geometric orifice area or small effective orifice area
re associated with increased operative mortality after isolated aortic valve replacement.
ven for valves with small effective orifice area, however, mortality decreases as body
urface area increases. With respect to operative mortality, therefore, our results do not
upport using arbitrary cutoff values of effective orifice area/body surface area to
etermine the valve to utilize in a given patient.
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A
CDontroversy exists regarding the importance of pa-
tient size and prosthesis internal orifice size on both
early and late mortality after aortic valve replace-
ent (AVR) surgery.1-16 We can summarize the contr-
ersy as revolving around 4 key issues: (1) How do we
efine the most hemodynamically relevant index of aortic
rosthesis internal orifice size? (2) However defined, is an
ppropriate, calculable, or measurable index of internal aor-
ic prosthesis size an independent predictor of short-term or
ong-term morbidity and mortality after AVR? (3) What is
he nature of the interaction between the defined index and
atient size as predictors of operative mortality? (4) How
hould the conduct of AVR surgery be influenced—including
he selection of an aortic prosthesis for a given patient—by
onsiderations related to patient size and an appropriate index
f prosthesis internal orifice size?
The term prosthesis–patient mismatch was first coined
y Rahimtoola1 and has been used extensively in the l-
ture to describe the use of a prosthesis of a given type that
s “too small” for a patient of a given size. He defined it to
ccur when “the effective prosthetic valve area, after inser-
ion into the patient, is less than that of a normal human
alve.”1 We now know that with the possible exceptio
ortic homografts and pulmonary autografts, all biopros-
hetic and all mechanical valves are associated with some
egree of mismatch by this definition.3,16 As outlined
bove, controversy exists as to the most hemodynamically
elevant index of prosthesis internal orifice size. It is well
ppreciated that a manufacturer’s labeled valve size (eg, 19
m, 21 mm, etc) is not consistently defined across different
anufacturers.17,18 For any given manufacturer, the intern
rifice diameter is always less than the manufacturer’s la-
eled size. Marked differences in internal orifice area
equivalent to geometric orifice area [GOA]) and external
iameter exist by manufacturer for mechanical, stented, and
tentless bioprostheses. For aortic homografts, the manufac-
urer’s labeled size is equal to the internal orifice diameter,
nd for the Toronto stentless porcine valve (St Jude Medi-
al, Minneapolis, Minn) and the Medtronic Hall valve
Medtronic, Minneapolis, MN), it is equal to the external
iameter of the valve; for most other mechanical valves, the
xternal diameter is 3 to 5 mm larger than the manufactur-
r’s labeled size.17,18
As a result of this confusing nomenclature, most studies
hat have attempted to relate prosthesis internal orifice size
o long-term or short-term mortality have eschewed the use
f manufacturer’s labeled valve size as a covariate as it is
ot a robust predictor (across different valve types and
anufacturers) of the functional relationship between pres-
ure gradient and flow for a given aortic valve prosthesis.
ather, indices of prosthesis internal orifice size such as the
rojected in vivo effective orifice area (EOA) or GOA have
een utilized.3-10,15 More recently, GOA/body surface area A
The Journal of ThoracicBSA) has been proposed as an index of prosthesis internal
rifice size.3-5 Using GOA/BSA as an index of prosthe
nternal orifice size, Blackstone and colleagues3 found that
OA/BSA was not a significant independent predictor of
ntermediate-term survival and that for mechanical valves
ut not for bioprosthetic valves, GOA/BSA was a signifi-
ant but weak predictor of 30-day mortality. In contrast,
lais and colleagues6 found that EOA indexed by BS
EOA/BSA) was a robust multivariable predictor of opera-
ive mortality and that patients with EOA/BSA 0.65
m2/m2 had an odds ratio (OR) of 11.4 (4.4-29.5) for
perative mortality compared with those with EOA/BSA 
.85 cm2/m2. Furthermore, these authors argue that EOA
projected or estimated in vivo) rather than GOA is the most
emodynamically relevant preoperative index of prosthesis
nternal orifice size because it is more highly correlated with
ressure gradients that occur during left ventricular ejec-
ion.7,8,19 These considerations notwithstanding, others3-5
ave argued that because actual (rather than projected
ivo EOA varies with exercise, aortic anatomy, and hemo-
ynamics,20-24 GOA is a more robust index of hemodyn-
cally relevant prosthesis internal orifice size.
Here, in contrast to previous studies,3-10,15 we do no
ecide a priori which index of internal prosthesis orifice size
o utilize. Rather, we used multivariable models with data
erived from the Society of Thoracic Surgeons (STS) Na-
ional Cardiac Database to assess the significance of both
rojected in vivo EOA and GOA as independent predictors
f operative mortality after isolated AVR. We also deter-
ine the independent predictive value of BSA as well as
elected indices derived from rational combinations of EOA
r GOA and BSA (eg, EOA/BSA) on operative mortality.
aterials and Methods
TS Database
he STS National Cardiac Database was established in 1989 to
eport surgical outcomes following cardiothoracic surgical proce-
ures.25 Sites enter patient data using uniform definitions (av-
ble online at http://www.sts.org) and certified software syste
Abbreviations and Acronyms
AVR  aortic valve replacement
BMI  body mass index
BSA  body surface area
CABG  coronary artery bypass graft surgery
CI  confidence interval
EOA  effective orifice area
GOA  geometric orifice area
NYHA New York Heart Association
OR  odds ratio
STS  Society of Thoracic Surgeonslthough participation in the STS database is voluntary, data com-
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1
A
CDleteness is high, with overall preoperative risk factors missing in
ewer than 5% of submitted cases. The accuracy of submitted cases
as been confirmed in independent comparison of hospital coronary
rtery bypass graft surgery (CABG) volume and mortality rates re-
orted to the STS versus those reported to Centers for Medicare and
edicaid Services.26
atient Population
atients in the STS adult cardiac database who had isolated aortic
alve replacement surgery with a prosthetic valve from January 1,
000 to December 31, 2004 were considered for inclusion in the
tudy. Patients having concomitant procedures such as multiple-
alve or CABG surgery were excluded, leaving 48,722 patients.
he analysis was further restricted to 42,880 patients receiving 1 of
he 8 most prevalent valve types in the database (mechanical pros-
heses: Carbomedics (Austin, Tex), Medtronic-Hall, St Jude Medical;
tented bioprostheses: Carpentier–Edwards Pericardial (Edwards Life
ciences, Irvine, Calif), Hancock II Porcine (Medtronic), Medtronic
osaic Porcine; stentless porcine prostheses: Medtronic, Toronto
PV) and the 6 most prevalent manufacturers’ labeled sizes (19 mm,
1 mm, 23 mm, 25 mm, 27 mm, 29 mm). We excluded the small
inority of valves with even manufacturer’s labeled sizes from the
nalysis. Patients with status coded as “salvage” were excluded (n 
5) as well as subjects with missing data on 6 key variables (age,
ender, BSA, body mass index [BMI], height, and weight), leaving a
ample of 42,310 patients in 646 hospitals. Patients who received a
alve for which EOA or GOA data were unavailable were excluded
rom multivariable models utilizing that variable. Patient characteris-
ics are summarized in Table 1. Missing values are excluded.
ndices of Prosthesis Internal Orifice Size and
atient Size
ll estimates of projected in vivo EOA and most estimates of
OA were also obtained from the literature, and other estimates of
OA were obtained directly from the manufacturers (Table
ost of the projected EOA values taken from the literature were
erived by performing Doppler imaging studies on patients who
ad undergone aortic valve replacement surgery and then calcu-
ating the average Doppler-estimated EOA among patients having
he same prosthesis model and label size. Estimates of EOA were
vailable for all but 5 of the 48 manufacturers’ labeled valve-size-
odel combinations included in the analysis, and estimates of
OA were available for all but one manufacturer’s labeled valve-
ize-model combination.
BSA was estimated for each patient using the Dubois and
ubois formula27: BSA (m2)  0.007184  height (cm)0.725 
eight (kg)0.425.
linical End Point
he primary end point, operative mortality, is defined as death
uring the same hospitalization as surgery or after discharge but
ithin 30 days of surgery. Additional data definitions are available
t www.sts.org.
ultivariable Analyses
everal logistic regression models were developed to assess the
ssociation between surrogates of patient size (BSA) and prosthe-
is internal orifice size (EOA or GOA) and operative mortality e
014 The Journal of Thoracic and Cardiovascular Surgery ● Aprhile adjusting for covariates. In the first set of analyses, variables
elating to patient size and prosthesis internal orifice size included:
OA, EOA2, 1/BSA, 1/BSA2, EOA/BSA, EOA2/BSA2. We also
erformed parallel analyses by substituting GOA for EOA in the
ist of variables. The quadratic terms (EOA2 or GOA2) allow the
stimated relationship between prosthesis internal orifice size and
ortality to be nonlinear on the log-odds scale. The ratio terms
OA/BSA and EOA2/BSA2 (or GOA/BSA and GOA2/BSA2) al-
ow the shape of the relationship between prosthesis internal
rifice size and mortality to depend on the patient’s body size.
onversely, these ratio terms allow the shape of the relationship
etween BSA and mortality to depend on the valve’s estimated
nternal orifice size. We also fit these models without including the
atio terms to estimate the average association between internal
rifice size and mortality averaging over body size. Additional
ariables in each model were: patient age (modeled as a 2-phase
inear function with a change of slope at 75 years), diabetes, renal
ailure, dialysis, hypertension, cerebrovascular accident, infective
ndocarditis, chronic lung disease, peripheral vascular disease,
eoperation, New York Heart Association (NYHA) class IV, pul-
onary hypertension, myocardial ischemia within 3 weeks, status
elective, urgent, emergent), preoperative intra-aortic balloon
ump, gender, ejection fraction less than 40, aortic stenosis, aortic
nsufficiency, congestive heart failure, cerebrovascular disease,
rrhythmia, nonwhite race, obesity (BMI 35 kg/m2), and year of
urgery. An assumption of the model (made for simplicity) is that
alve-related variables do not interact with patient factors other
han BSA. We tested this assumption and found that it did not have
significant impact on the results. Substituting BSA for 1/BSA in
he regression models also had little impact on the results.
Inferences about the association between indices of prosthesis
nternal orifice size and mortality are potentially confounded by
everal factors including: (1) unmeasured intrinsic valve charac-
eristics peculiar to each valve model and (2) measurement error in
he assessment of a valve’s projected EOA or GOA. Two different
pproaches were used to adjust for these sources of confounding.
irst, we fit the logistic regression models by including fixed-effect
ndicator variables for each valve model. This approach adjusts for
ny valve-related factors that might impact mortality through
echanisms unrelated to the valve’s internal orifice size. This is
ppropriate because the risk of mortality could potentially vary by
alve model, even among valve models having the same internal
rifice size. In these analyses, parameters describing the “effect” of
OA or GOA on mortality pertain to differences in manufacturers’
abeled valve size when the valve model is held constant. Second,
e fit random effects logistic regression models that included
andom effects for each combination of manufacturer model and
abeled size. The inclusion of random effects allows for an unob-
erved valve-level component specific to each combination of
odel and label size. These random effects capture any valve-level
actors that were omitted from the model that might systematically
ncrease or decrease the risk of mortality among patients receiving
he same valve model and label size. In addition, this approach
ccounts for potential measurement error in the estimation of
verage EOA and GOA by subsuming the true EOA and GOA
alues into the random effects component. The results of both
odeling approaches were similar with respect to both pointstimates and confidence intervals (CIs). For brevity, only the
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A
CDxed effect analyses are presented. These analyses were first
erformed using all patients in the study population and were
ubsequently repeated in the subpopulation of patients having
MI  30 and in patients who received manufacturers’ labeled
alve sizes 19 or 21.
We summarized the results of the multivariable models by
resenting ORs along with their asymptotic 95% CIs. These ORs
escribe the relative increase or decrease in the estimated odds of
ortality as a function of valve internal orifice size (EOA or GOA)
ompared with a reference size of EOA  2.0 cm2 or GOA  5.0
m2. We also displayed the model results graphically, by plotting
stimated mortality risk as a function of valve internal orifice size
EOA or GOA) and body size (BSA). For these plots, “risk-
djusted mortality” is defined as the predicted probability of mor-
ality for a patient having the indicated values of EOA or GOA and
SA and a hypothetical baseline risk of mortality loosely corre-
ponding to “average risk.” The baseline risk was determined by
equiring that the average risk-adjusted mortality rate (obtained by
veraging across all of the observed values of EOA, GOA, and
SA in the study population) be equal to the observed mortality
ABLE 1. Continued
haracteristic
Totals
n Percentage
ortic insufficiency
None 15,601 37.93
Trivial 3538 8.60
Mild 5632 13.69
Moderate 5703 13.87
Severe 10,655 25.90
eoperation 7083 16.81
revious cardiovascular intervention 9255 21.91
ongestive heart failure 16,635 39.46
yocardial infarction 3706 8.78
ardiogenic shock 289 0.68
esuscitation 168 0.40
YHA class
I 6442 16.09
II 11,096 27.72
III 16,813 41.99
IV 5690 14.21
tatus
Elective 33,714 79.81
Urgent 8129 19.24
Emergent 399 0.94
iabetes 8512 20.17
enal failure 2527 5.99
ialysis 859 2.04
ypertension 26,431 62.64
ypercholesterolemia 18,028 42.84
revious cerebrovascular accident 2803 6.64
eripheral vascular disease 4816 11.41
reoperative arrhythmia 6688 15.85
nfectious endocarditis 2123 5.03
YHA, New York Heart Association.ABLE 1. Patient characteristics
haracteristic
Totals
n Percentage
24,479 57.86
17,831 42.14
ace
White 37,284 88.95
Black 2069 4.94
Other 2562 6.12
ge (y)
40 1813 4.29
40-49 3553 8.40
50-59 6439 15.22
60-69 9600 22.69
70-79 13,946 32.96
80 6959 16.45
MI
18-24 11,644 27.85
25-29 15,420 36.89
30-34 8677 20.75
35 6069 14.51
SA
1.50 1558 3.68
1.50-1.74 8921 21.08
1.75-1.99 15,867 37.50
2.00-2.24 11,915 28.16
2.25-2.49 3387 8.01
2.50 662 1.56
jection fraction
30 2223 5.86
30-39 3164 8.36
40-49 5118 13.52
50 27,371 72.26
alve type
Mechanical 13,653 32.27
Stented bio 25,640 60.60
Stentless bio 3017 7.13
echanical valve
No 28,657 67.73
Yes 13,653 32.27
alve model
CarboMedics Mechanical 2398 5.67
St Jude Medical Mechanical 10,636 25.14
Carpentier–Edwards Perimount 18,776 44.38
Medtronic Hall Mechanical 619 1.46
Hancock II Porcine 2721 6.43
Medtronic Freestyle Stentless 1845 4.36
Medtronic Mosaic Porcine 4143 9.79
St Jude Medical–Toronto SPV Stentless 1172 2.77
anufacturer’s labeled valve size (mm)
19 4107 9.71
21 11,700 27.65
23 13,172 31.13
25 8511 20.12
27 3691 8.72
29 1129 2.67ate in the study population.
and Cardiovascular Surgery ● Volume 133, Number 4 1015
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A
CDesults
atient Characteristics
he characteristics of our patient population are summa-
ized in Table 1. Fifty-eight percent of our patients 
en, 89% were white, and most had a normal ejection
raction (72% were greater than 50%). Despite the relatively
reserved left ventricular function, over 50% had significant
ABLE 3. Frequencies of valves in study population
labeled sizes 19, 21, 23, 25, 27, 29)
alve
Number of
patients (%)
1 (Carbomedics Mechanical Prosthesis) 2398 (5.7)
2 (Medtronic–Hall Mechanical Prosthesis) 619 (1.5)
3 (St Jude Medical Mechanical Prosthesis) 10,636 (25.1)
1 (Carpentier–Edwards Pericardial
ioprosthesis)
18,776 (44.4)
2 (Hancock II Porcine Bioprosthesis) 2721 (6.4)
3 (Medtronic Mosaic Porcine Bioprosthesis) 4143 (9.8)
1 (Medtronic Freestyle Stentless Porcine) 1845 (4.4)
2 (St Jude–Toronto SPV Stentless Porcine) 1172 (2.8)
otal 42,310 (100)
ABLE 2. Estimated EOA and GOA by valve model and size
Estimated EOA (cm2)
19 mm 21 mm 23 mm 25 mm 27 mm 29 mm
1 1.0028 1.5428 1.6328 1.9828 2.4128 2.6328
2 N/A 1.2533 1.5633 2.1733 2.1133 2.2533
3 1.0429 1.3829 1.5229 2.0829 2.6529 3.2329
1 1.1030 1.3030 1.5030 1.8030 1.8030 N/A
2 N/A 1.1834 1.3334 1.4634 1.5534 1.6034
3 1.2031 1.2231 1.3831 1.6531 1.831 2.031
1 1.1532 1.3532 1.4832 2.0032 2.3232 N/A
2 N/A 1.30* 1.49* 1.70* 2.00* 2.50*
Estimated GOA (cm2)
19 mm 21 mm 23 mm 25 mm 27 mm 29 mm
1 1.7017 2.1917 2.6917 3.3017 3.9817 N/A
2 N/A 2.0117 2.5417 3.1417 3.8017 4.5217
3 1.7017 2.1917 2.6917 3.2717 3.9117 4.5617
1 2.5417 3.1417 3.8017 4.5217 5.3117 6.1617
2 2.0917 2.6317 3.2017 3.8417 4.1217 4.7917
3 2.41* 2.69* 3.30* 3.98* 4.52* 5.31*
1 2.01* 2.54* 3.14* 3.63* 4.34* 5.11**
2 1.7717 2.2717 2.8417 3.4617 4.1517 4.9117
echanical prostheses: M1, Carbomedics; M2, Medtronic-Hall; M3, St.
ude Medical. Stented bioprostheses: B1, Carpentier-Edwards Pericardial;
2, Hancock II Porcine; B3, Medtronic Mosaic Porcine. Stentless porcine
rostheses: S1, Medtronic; S2, Toronto SPV. Superscripts refer to the
riginal reference sources (see also reference 3) EOA, effective orifice
rea; GOA, geometric orifice area; N/A, Not available. *Data provided by
he manufacturer.echanical prostheses definitions in Table 2.
016 The Journal of Thoracic and Cardiovascular Surgery ● Apreart failure symptoms (NYHA class III or IV). Hypertension
as common (63%); roughly one third of the valves implanted
ere mechanical and two thirds were tissue valves.
istribution of Valve Types
n Tables 2 and 3 we summarize the GOA and EOA 
sed and the manufacturers and types of valves included in
he analysis as well as their respective frequencies in the
ata set. St Jude Mechanical prostheses and Carpentier
dwards pericardial prostheses together represent 70% of
he valves in the data set.
ultivariable Analyses
n separate parallel analyses, decreasing GOA and decreasing
OA compared with their respective reference values were
oth strongly associated with increasing operative mortality
isk, regardless of the patient’s body size (Tables 4 a
igures 1 and 2). For average-sized patients (BSA  2.0 m2),
decrease in EOA from 2.00 cm2 to 1.50 cm2 is associated
ith a 35% increase in the odds of mortality (OR 1.35; 95%
I [1.21, 1.52]), and a 0.75 cm2 decrease in EOA (2.00 cm2 vs
.25 cm2) is associated with a 73% increase in the odds of
ortality (OR  1.73; 95% CI [1.42, 2.11]). Results were
imilar when GOA was used as an index of prosthesis internal
rifice size. The estimated shape of the relationship between
OA (or GOA) and log-odds of mortality was generally sim-
lar regardless of the patient’s body size (Figure 1). In 
ariable models, we tested whether the interaction between
SA and valve size (as expressed as either EOA or GOA) was
ignificant: it was not (P  0.145 for BSA/EOA interaction,
df; P  0.2527 for GOA/BSA interaction, 2df; etc). As a
esult, we do not conclude that the relationship between GOA
r EOA and mortality depends strongly on the BSA of the
atients. Results did not change when the analysis was re-
tricted to nonobese patients (BMI  30) or patients with a
small” aortic annulus (manufacturers’ labeled valve size 19 or
1; Tables E1 through E4).
Regardless of the EOA or GOA of the valve inserted, we
ound that operative mortality generally decreased with
ncreasing BSA (Figures 1, 2, and 3). This implies 
mong patients receiving the same manufacturer’s model
TABLE 4. Adjusted ORs for GOA at selected values of BSA
BSA
GOA (cm2)
4.0 vs 5.0 3.0 vs 5.0 2.0 vs 5.0
1.50 1.06 (0.72, 1.57) 1.32 (0.75, 2.31) 1.90 (1.06, 3.41)
1.75 1.15 (0.94, 1.41) 1.56 (1.17, 2.07) 2.46 (1.76, 3.43)
2.00 1.23 (1.02, 1.49) 1.77 (1.36, 2.30) 2.98 (2.15, 4.14)
2.25 1.29 (1.04, 1.60) 1.96 (1.45, 2.65) 3.47 (2.27, 5.30)
2.50 1.34 (1.07, 1.70) 2.12 (1.50, 3.00) 3.92 (2.24, 6.88)
All 1.25 (1.05, 1.50) 1.76 (1.36, 2.27) 2.76 (2.02, 3.77)OR, odds ratio; GOA, geometric orifice area; BSA, body surface area.
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A
CDnd labeled size, increasing degrees of “mismatch” as de-
ned by decreasing the ratio of EOA/BSA or GOA/BSA is
enerally associated with better outcomes, not worse out-
omes. Point estimates from the model containing GOA
Figure 3) suggest that the trend may reverse itself 
SA is greater than about 2.0; that is, BSA may exhibit a
-shape relationship with operative mortality. These results
re potentially provocative, suggesting that in the small
raction of patients with extremely small GOA and large
SA, patient prosthesis mismatch may become an impor-
ant phenomenon. From a statistical point of view, however,
ur analysis yielded no significant evidence of an interac-
ion between the internal orifice size of the valve implanted
using GOA or projected in vivo EOA as an index) and the
hape of the curve relating BSA to mortality. Moreover, the
pparent upturn in mortality disappeared when the nonsig-
ificant ratio terms (GOA/BSA and GOA2/BSA2) were
emoved from the logistic regression model.
iscussion
ur study provides strong evidence of a clinically mean-
ngful association between indices of prosthesis internal
igure 1. Estimated risk-adjusted mortality rate as a function of
ABLE 5. Adjusted ORs for EOA at selected values of BSA
SA 1.75 vs 2.0 1.5 vs 2.
1.50 1.02 (0.92, 1.14) 1.17 (0.95, 1
1.75 1.09 (1.03, 1.16) 1.30 (1.15, 1
2.00 1.13 (1.06, 1.19) 1.35 (1.21, 1
2.25 1.14 (1.06, 1.22) 1.36 (1.16, 1
2.50 1.14 (1.03, 1.26) 1.35 (1.08, 1
ll 1.12 (1.06, 1.18) 1.34 (1.20, 1
Rs, odds ratios; EOA, effective orifice area; BSA, body surface area.SA and EOA. BSA, body surface area; EOA, effective orifice area. a
The Journal of Thoracicrifice size and operative mortality. It does not indicate that
he observed association is causal or dependent on the
atient’s BSA. Although it is impossible to test this hypoth-
sis directly, the higher mortality associated with low EOA/
SA or GOA/BSA ratios is usually presumed to result from
orse hemodynamic performance of valves that have an
nternal orifice size that is too small relative to the size of
EOA (cm2)
1.25 vs 2.0 1.0 vs 2.0
1.49 (1.10, 2.02) 2.13 (1.37, 3.30)
1.68 (1.38, 2.04) 2.35 (1.75, 3.17)
1.73 (1.42, 2.11) 2.38 (1.74, 3.24)
1.72 (1.29, 2.30) 2.30 (1.46, 3.62)
1.68 (1.12, 2.52) 2.19 (1.16, 4.10)
1.72 (1.43, 2.06) 2.36 (1.78, 3.13)
igure 2. Estimated association between BSA and risk-adjusted
ortality as a function of EOA. , EOA  1.2 cm2; ●, EOA  1.4
m2; Œ, EOA  1.6 cm2; , EOA  1.8 cm2. BSA, body surface0
.43)
.47)
.52)
.60)
.70)
.50)rea; EOA, effective orifice area.
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CDhe patient. Underpinning this assumption is the hypothesis
hat if an excessive amount of energy is expended by the left
entricle to pump blood across such a valve, there will be a
etrimental impact on operative mortality and that because
ardiac output increases linearly with BSA, the effect
hould become more pronounced as BSA increases for a
iven prosthesis internal orifice size. Unlike other investi-
ators,3-8 in our multivariable analyses, we did not assu
priori that EOA or GOA should be considered only in
elation to BSA. In addition, our analysis allowed for the
ossibility that BSA might have its own independent effect
n mortality, quite apart from considerations related to
rosthesis internal orifice size. The main finding of these
nalyses was that the magnitudes of the associations be-
ween our proxy measures of prosthesis internal orifice size
EOA and GOA) and mortality do not vary substantially
epending on the patient’s BSA. Thus although there are
umerous possible explanations for this negative finding,
igure 3. Estimated association between BSA and risk-adjusted
ortality as a function of GOA. , GOA  2.0 cm2; ●, GOA  3.0
m2; Œ, GOA  4.0 cm2;, GOA  5.0 cm2). BSA, body surface
rea; GOA, geometric orifice area.e do not feel that the interaction between patient size and c
018 The Journal of Thoracic and Cardiovascular Surgery ● Aprrosthesis internal orifice size is the driving force for the
bserved association between prosthesis internal orifice size
nd operative mortality in the present study. This conclu-
ion is reflected by the lack of significance of EOA/BSA or
OA/BSA in models that include EOA or GOA,
espectively.
The notion of prosthesis–patient mismatch implies that
or a fixed valve model and manufacturer’s labeled valve
ize, and holding all other factors constant, patients with
arger BSA will have worse outcomes than patients with
mall BSA. In fact, we found no evidence of worse
utcomes among patients with larger BSA after stratifi-
ation by prosthesis internal orifice size as defined by
OA or GOA. On the contrary, larger BSA (ie, lower
OA/BSA) was generally associated with lower opera-
ive mortality regardless of the valve model and manu-
acturer’s labeled valve size inserted. This finding is
onsistent with the interpretation that unmeasured con-
ounder variables that lead to a protective effect of in-
reasing BSA appear to be more important determinants
f operative mortality than what others have called
mismatch.”
When BSA is held constant, we found that mortality
ppears to increase with decreasing values of EOA. Al-
hough it is also true that mortality increases as a function of
OA/BSA (treating BSA is a constant), we did not find
ompelling statistical evidence to support using EOA/BSA
s a criterion for valve selection. In fact, because the ratio
erm EOA/BSA is nonsignificant in a model that includes
OA and 1/BSA as main effects, there is no evidence to
onclude that the relationship between EOA and mortality
epends on the patient’s BSA. Therefore, our data do not
rovide support for the convention of measuring EOA/BSA
nd using specific cutoffs in an effort to decrease operative
ortality.
Taking a balanced interpretation of our results, it is
mportant to note that our results also cannot exclude a
ignificant causal mechanism related to hemodynamics
“mismatch”) in a subset of patients. The lack of interaction
etween indices of prosthesis internal orifice size and BSA
ay be due to measurement error, the use of imperfect
roxy variables, or unmeasured confounder variables.
onetheless, it appears that the potential negative effects of
oor hemodynamic performance of valves with small EOA
r GOA may be overwhelmed by the operative mortality
dvantage of larger BSA. We can speculate that the appar-
nt independent protective effect of increasing BSA may
imply reflect relative ease of valve implantation in patients
ith larger aortic annuli and an attendant decrease in tech-
ically related complications. We did not find any clear
utoff values for EOA that are acceptable or unacceptable.
ther than the dependence on EOA, we also did not find aonsistent independent relationship of the type of valve by
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A
CDanufacturer on operative mortality. Our data neither refute
or confirm the contention3-5 that GOA, because of 
obustness, is preferable to projected in vivo EOA as a
ractical preoperative index of prosthesis internal orifice
ize.
onclusions
nlike our own analysis, Blais and colleagues6 included
atients who had AVR combined with CABG. Because we
imited ourselves to patients with isolated AVR, we cannot
xclude the possibility that in patients with impaired left
entricular function35 or coronary artery disease, prosthesi
atient mismatch may be a clinically important phenome-
on, hypothetically as a result of concerns related to the
nergy supply-demand ratio. We would predict that this
ight occur more commonly in large patients (high energy
emand) with small prostheses (greater myocardial energy
oss with ejection) when combined with flow-limited oxy-
en delivery to the left ventricular myocardium due to both
rolonged global ischemia and residual coronary ischemia
fter revascularization. Furthermore, our study provides no
nsight into the potential negative impact of aortic prosthe-
es with small internal orifice area on left ventricular mass
egression or on long-term mortality.36,37
In the version of the STS software available during this
tudy, the type of St Jude valve was not specified, and the EOA
alues used were those for standard (rather than high profile
HP] or Regent) models. The Regent model was not even
vailable during the first 2 years of our study interval, and it
ikely was used in a very small proportion of our study group
atients. In other studies,3 the HP model represented only 6
f St Jude mechanical valves. Therefore, we estimate that
pproximately 90% of the patients did in fact have the standard
odel St Jude valve. We repeated the analysis excluding all St
ude valves (Tables E5 and E6) and the conclusions di
hange.
In summary, these data clearly demonstrate that small
rosthesis internal orifice size is associated with an increase
n operative mortality after isolated AVR. Our study does
ot provide an explanation for this finding. Although tech-
ical factors may be 1 possibility, we cannot exclude the
ossibility that worse hemodynamics are associated with
maller prosthesis size. Because operative mortality de-
reases in general as BSA increases for a given EOA or
OA, our results suggest that the protective effect of in-
reased BSA may confound the impact of any potential
egative hemodynamic effect of small EOA or small GOA.
e find that given EOA or GOA alone as covariates,
OA/BSA and GOA/BSA are not significant predictors of
perative mortality in multivariable models. We do not
dvocate the practice of using arbitrary cutoff values of
OA/BSA as a decision tool to determine the type or
anufacturer’s labeled size of valve to be utilized in a given
The Journal of Thoracict
atient in an attempt to decrease operative mortality. In terms
f selecting the type of valve or technique of valve replace-
ent, we believe that primary consideration should be given to
actors such as durability, surgeon experience, technical ease,
nd speed of implantation and factors influencing the choice of
bioprosthesis over a mechanical valve and vice versa. Once
hese factors have been considered, our data do suggest that it
ay be reasonable to give preference to valves with consis-
ently higher projected in vivo EOA or GOA values. Without
onfirmatory randomized trial data to mitigate unmeasured
onfounder variables, there is insufficient data to validate the
ractice of using the EOA/BSA ratio as a method for selecting
he valve to be used in a given patient.
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020 The Journal of Thoracic and Cardiovascular Surgery ● Apriscussion
r George T. Christakis (Toronto, Canada). The authors are to be
ongratulated for this work, which adds substantially to the knowl-
dge base of aortic valvular prosthesis size and its purported influence
n operative mortality. The authors have used contemporary data
rom a homogenous population undergoing aortic valve replacement.
he cohort is large with good statistical predictive power. Dr. Bridges
nd his colleagues performed multivariable analyses and demon-
trated that effective orifice area or indexed effective orifice area, but
ot both, were independent predictors of operative mortality follow-
ng aortic valve replacement.
We in Toronto have previously published data confirming an
ncrease in operative mortality following aortic valve replacement
hen the indexed effective orifice area is less than 0.6 cm2/m2. We
emonstrated operative mortalities of 2.1% versus less than 1%
epending on whether they were above or below 0.6 cm2/m2. We
lso demonstrated that an indexed effective orifice area less than
.6 cm2/m2 represented the 10th percentile for patient prosthesis
ize. This is, coincidentally, the exact cutoff Dr Bridges and
olleagues have used to represent the lowest indexed effective
rifice area.
In model 3, where both effective orifice area and indexed
ffective orifice area were used together in the model, the authors
emonstrated that indexed effective orifice area did not predict
perative mortality and only an effective orifice area less than 1.15
m2 barely predicted operative mortality, with a lower-end confi-
ence interval for an OR of 1.04.
Do Dr Bridges and colleagues believe that perhaps effective
rifice area is not a predictor of operative mortality but rather a
linical correlate or a confounding variable or a proxy variable that
ruly predicts operative mortality?
The small valve implant may not have been the cause of death.
his introduces a plethora of questions. Were other variables or
nteractions of other variables tested in the models? What was the
redictive value in the authors’ best model based on a receiving
perating characteristics curve? Could left ventricular function,
ender, or valve lesion be a proxy for effective orifice area? And
am sure many of the sponsoring manufacturers would like to
now whether the type and make of valve influenced the operative
ortality.
Finally, the authors conclude that a small prosthesis size in-
reases operative mortality following AVR, presumably on the
asis of patient-prosthesis mismatch theory, but I believe on the
asis of this conclusion that they do not think that the cause is
emodynamic. An alternative explanation may be that the opera-
ive mortality is increased by the complications associated with
mplanting any valve into a small annulus. Obstruction of coro-
aries, the need to perform aortoplasties or annuloplasties, para-
alvular leaks, and tearing of the aorta from tying in a small hole
re more common in patients with small annuli and friable tissues
hat usually occur in patients like this.
We caution the authors that conclusions that insinuate it is the
mall prosthesis that increases operative mortality rather than the
mall annulus may become a self-fulfilling prophecy. Concerted
ttempts to stuff even larger valves into small annuli may cause
omplications such as torn aortas and obstructed coronaries. Sur-
eons may be compelled to perform aortic root enlargement pro-
edures or other complicated procedures with an accompanying
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Bridges et al Surgery for Acquired Cardiovascular Diseaseigher operative mortality under the false impression that it is the
mall valve that is causing a higher operative mortality.
We suggest that further study is necessary to understand how
mall aortic annuli increase operative mortality, what the mecha-
ism of complications is, and what techniques can be used to
ecrease the complication rate rather than focusing on the size of
he implanted prosthesis. Do the authors know the mechanism of
perative mortality in their patients, and what was the incidence
f aortic root enlargement or aortoplasties?
Dr. Charles R. Bridges (Philadelphia, Pa). Thank you very
uch, Dr. Christakis, for those insightful questions. I will try to
nswer each of them. You asked whether effective orifice area is
othing more than a clinical correlate or a proxy variable for some
ther variable that is actually the cause of increased mortality. We
on’t know the answer to that, but we believe that effective orifice
rea itself is not likely to be the most important variable, and in
act, we actually agree very much with you that small prosthesis
ize may be a surrogate or a proxy for small annular size and the
echnical issues associated with implanting valves in relatively
mall annuli. r
The Journal of ThoracicIn terms of whether there is a relationship of the type and make
f valve, there is a slight difference in mortality for mechanical
rostheses compared to bioprostheses; however, we could not find
ny consistent relationship by manufacturer of mortality, and ob-
iously that was not the primary purpose of this study.
The other point you made was that it probably is the small
nnulus that is the cause of increased mortality associated with
mall prostheses, not the size of the prosthesis itself. Our
nalysis suggests that hemodynamics is not an important factor
n the increased mortality associated with these small valves. If
t were, we would have expected that the mortality would have
otten even higher when small valves were placed in larger
atients. In fact, we did not find that to be the case, which
nderlines and echoes your point that it may have little to do
ith hemodynamics.
And I wholeheartedly agree with your assertion that an attempt
o put larger valves in small patients, simply based on arbitrary
utoffs, may actually do more harm than good, although that
ould need to be the subject of an additional study, ideally, aandomized trial.
and Cardiovascular Surgery ● Volume 133, Number 4 1021
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CDABLE E1. Adjusted ORs for GOA at selected values of BS
SA 2.25 vs 2.5
1.50 1.08 (0.97, 1.20)
1.75 1.12 (1.02, 1.24)
2.00 1.15 (1.03, 1.29)
2.25 1.18 (1.01, 1.37)
2.50 1.19 (0.97, 1.47)
ll 1.11 (1.01, 1.22)
Rs, odds ratios; GOA, geometric orifice area; BSA, body surface area.
ABLE E2. Adjusted ORs for EOA at selected values of BS
SA
1.50
1.75
2.00
2.25
2.50
llA (limited to manufacturer’s labeled valve sizes 19 and 21)
GOA (cm2)
2.0 vs 2.5 1.75 vs 2.5
1.17 (0.91, 1.50) 1.27 (0.81, 1.98)
1.26 (1.00, 1.58) 1.41 (0.95, 2.10)
1.33 (1.02, 1.73) 1.53 (0.96, 2.43)
1.38 (0.96, 1.98) 1.62 (0.86, 3.04)
1.42 (0.88, 2.31) 1.69 (0.74, 3.89)
1.23 (0.98, 1.53) 1.35 (0.91, 1.99)A (limited to manufacturer’s labeled valve sizes 19 and 21)
EOA (cm2) 1.0 vs 1.25
0.85 (0.44, 1.66)
0.80 (0.43, 1.52)
0.84 (0.43, 1.65)
0.92 (0.39, 2.15)
1.02 (0.33, 3.10)
0.86 (0.46, 1.60)Rs, odds ratios; EOA, effective orifice area; BSA, body surface area.
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ORs, odds ratios; GOA, geometric orifice area; BSA, body surface area; BMI, body mass index.
Bridges et al Surgery for Acquired Cardiovascular DiseaseABLE E4. Adjusted ORs for EOA at selected values of BSA (limited to patients with BMI < 30 kg/m2)
SA
EOA (cm2)
1.75 vs 2.0 1.5 vs 2.0 1.25 vs 2.0 1.0 vs 2.0
1.50 0.99 (0.87, 1.12) 1.08 (0.85, 1.37) 1.31 (0.92, 1.87) 1.75 (1.04, 2.93)
1.75 1.10 (1.02, 1.18) 1.28 (1.11, 1.48) 1.58 (1.26, 1.98) 2.08 (1.48, 2.92)
2.00 1.15 (1.06, 1.25) 1.37 (1.16, 1.62) 1.68 (1.26, 2.25) 2.14 (1.35, 3.39)
2.25 1.17 (1.04, 1.32) 1.40 (1.08, 1.81) 1.69 (1.07, 2.66) 2.07 (1.00, 4.26)
2.50 1.18 (1.00, 1.38) 1.39 (0.96, 2.00) 1.64 (0.86, 3.11) 1.94 (0.71, 5.26)
ll 1.12 (1.04, 1.20) 1.31 (1.14, 1.50) 1.61 (1.29, 2.01) 2.08 (1.48, 2.93)Rs, odds ratios; EOA, effective orifice area; BSA, body surface area; BMI, body mass index.ABLE E5. Adjusted ORs for GOA at selected values of BSA (excluding St Jude valves)
SA
GOA (cm2)
4.0 vs 5.0 3.0 vs 5.0 2.0 vs 5.0
1.50 1.03 (0.67, 1.57) 1.35 (0.75, 2.43) 2.27 (1.22, 4.22)
1.75 1.13 (0.90, 1.41) 1.58 (1.17, 2.12) 2.74 (1.90, 3.95)
2.00 1.19 (0.97, 1.46) 1.73 (1.31, 2.27) 3.04 (2.05, 4.52)
2.25 1.23 (0.98, 1.55) 1.82 (1.31, 2.54) 3.24 (1.79, 5.86)
2.50 1.26 (0.99, 1.61) 1.89 (1.24, 2.88) 3.36 (1.44, 7.85)
ll 1.18 (0.98, 1.44) 1.68 (1.29, 2.19) 2.86 (2.01, 4.05)Rs, odds ratios; GOA, geometric orifice area; BSA, body surface area.
A
CDTABLE E6. Adjusted ORs for EOA at selected values of BSA (excluding St Jude valves)
BSA
EOA (cm2)
1.75 vs 2.0 1.5 vs 2.0 1.25 vs 2.0 1.0 vs 2.0
1.50 0.97 (0.81, 1.18) 1.10 (0.80, 1.51) 1.44 (0.95, 2.17) 2.18 (1.27, 3.71)
1.75 1.06 (0.94, 1.19) 1.26 (1.04, 1.53) 1.69 (1.31, 2.19) 2.55 (1.79, 3.64)
2.00 1.10 (0.99, 1.23) 1.34 (1.12, 1.61) 1.81 (1.40, 2.33) 2.68 (1.82, 3.95)
2.25 1.12 (1, 1.27) 1.38 (1.10, 1.72) 1.84 (1.27, 2.65) 2.67 (1.47, 4.84)
2.50 1.13 (0.98, 1.30) 1.38 (1.03, 1.86) 1.82 (1.08, 3.08) 2.59 (1.11, 6.06)
All 1.09 (0.98, 1.21) 1.32 (1.11, 1.57) 1.75 (1.38, 2.22) 2.58 (1.84, 3.62)ABLE E3. Adjusted ORs for GOA at selected values of BSA (limited to patients with BMI < 30 kg/m2)
SA
GOA (cm2)
4.0 vs 5.0 3.0 vs 5.0 2.0 vs 5.0
1.50 1.13 (0.71, 1.79) 1.37 (0.71, 2.64) 1.78 (0.90, 3.50)
1.75 1.11 (0.89, 1.40) 1.43 (1.04, 1.97) 2.13 (1.47, 3.11)
2.00 1.14 (0.91, 1.44) 1.58 (1.15, 2.16) 2.64 (1.70, 4.09)
2.25 1.19 (0.91, 1.55) 1.76 (1.19, 2.60) 3.26 (1.71, 6.19)
2.50 1.24 (0.92, 1.66) 1.96 (1.21, 3.16) 3.96 (1.63, 9.62)
ll 1.18 (0.96, 1.45) 1.54 (1.15, 2.07) 2.24 (1.55, 3.25)ORs, odds ratios; EOA, effective orifice area; BSA, body surface area.
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